Review of trials currently testing treatment and prevention of COVID-19
Authors: P C Fragkou
C Skevaki
ESCMID Study Group for Respiratory Viruses
C D Moschopoulos
F-X Lescure
F Mentr√©
S Tsiodras
E Karofylakis
C Laou√©nan
D Belhadi
Y Yazdanpanah
H Janocha
N Peiffer-Smadja
Journal: Clinical Microbiology and Infection (2020)
Discipline: IMMUNOLOGY
Keywords: Anti-inflammatory; Antivirals; COVID-19; Clinical trials; Immunomodulators
Affiliations: 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland. Electronic address: ., Universit√© de Paris, IAME, INSERM, F-75018 Paris, France; D√©partement d'Epid√©miologie Biostatistiques et Recherche Clinique, H√¥pital Bichat - Claude-Bernard, AP-HP, 75018 Paris, France., Universit√© de Paris, IAME, INSERM, F-75018 Paris, France; Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique H√¥pitaux de Paris, Paris, France., 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL) Marburg, Germany., European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland; Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL) Marburg, Germany., 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland.

Abstract:  Background: As COVID-19 cases continue to rise globally, evidence from large randomized controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are being undertaken all over the world. Objectives: We summarized all registered clinical trials examining treatment and prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved studies. Data sources: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union Clinical Trials Register were systematically searched. Study eligibility criteria: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. No language, country or study design restrictions were applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative strategies for COVID-19. Participants and interventions: No restrictions in terms of participants' age and medical background or type of intervention were enforced. Methods: The registries were searched using the term 'coronavirus' or 'COVID-19' from their inception until 26 March 2020. Additional manual search of the registries was also performed. Eligible studies were summarized and tabulated. Interventional trials were methodologically analysed, excluding expanded access studies and trials testing traditional Chinese medicine. Results: In total, 309 trials evaluating therapeutic management options, 23 studies assessing preventive strategies and three studies examining both were retrieved. Finally, 214 studies were methodologically reviewed. Interventional treatment studies were mostly randomized (n = 150/198, 76%) and open label (n = 73/198, 37%) with a median number of planned inclusions of 90 (interquartile range 40-200). Major categories of interventions that are currently being investigated are discussed. Conclusions: Numerous clinical trials have been registered since the onset of the COVID-19 pandemic. Summarized data on these trials will assist physicians and researchers to promote patient care and guide future research efforts for COVID-19 pandemic containment. 

Retracted: No

PubPeer comments:
 Copy pasted from https: doi.org 10.1016 j.cmi.2021.01.024 :  Corrigendum to u201cReview of trials currently testing treatment and prevention of COVID-19u201d [Clin Microbiol Infect 26.8 (2020) 988u2013998]. The authors regret that at the u201cTransparency declarationu201d (p. 997) of the published paper, the conflicts of interest were unintentionally incomplete. The following is the correct u201cTransparency declarationu201d: For Y.Y.: Co-Chair of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and ACTion targeting emerging infectious diseases (REACTing); Presentations at workshops and consultancy honoraria from Abbvie, Gilead, Merck, J J, and ViiV Healthcare but not since 2017. For C.S.: Consultancy and research funding, Hycor Biomedical and Thermo Fisher Scientific; Consultancy, Bencard Allergie; Research Funding, Mead Johnson Nutrition . Supported by Universities Giessen and Marburg Lung Centre (UGMLC) , the German Center for Lung Research , University Hospital Giessen and Marburg research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft-funded-SFB 1021 (C04), -KFO 309 (P10), and SK 317 1-1 (Project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics. For FXL: Payment for development of educational presentations, Gilead Sciences, Inc. and MSD (Merck Sharp Dohme); Travel accommodations meeting expenses, Astellas Pharma Inc., Eumedica Pharmaceuticals, MSD (Merck Sharp Dohme). For PCF: Research funding, Doctorate scholarship by the State Scholarships Foundation ( IKY ), Partnership Agreement (PA) 2014-2020, co-financed by Greece and the European Union (European Social Fund - ESF ) through the Operational Programme u201cHuman Resources Development, Education and Lifelong Learning 2014-2020u201d. All grants are outside the submitted work. No external funding was received for this study. The authors would like to apologise for any inconvenience caused. Published online: February 01, 2021. ,